Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Denali Therapeutics Inc (NQ: DNLI )

63.90 USD -0.64 (-0.99%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 23, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 384,521
Open 64.73
Bid (Size) 62.00 (10)
Ask (Size) 80.00 (4)
Prev. Close 64.54
Today's Range 62.27 - 65.27
52wk Range 22.36 - 93.94
Shares Outstanding 121,192,210
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Denali Therapeutics to Present Interim Data from Phase 1/2 Study of ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at MPS 2021
Management to host webinar for analysts and investors on July 25th 
From GlobeNewswire News Releases
Denali Therapeutics Announces Initiation of Phase 2 Study by Partner Sanofi of RIPK1-Inhibitor DNL758 (SAR443122) in Cutaneous Lupus Erythematosus (CLE) Patients
From GlobeNewswire News Releases

Performance

YTD
-9.82%
-9.82%
1 Month
-10.04%
-10.04%
3 Month
+12.52%
+12.52%
6 Month
-19.25%
-19.25%
1 Year
+172.96%
+172.96%

More News

Read More
Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security I
From PR Newswire
Senda Biosciences Announces Closing of $98 Million Series B Financing
From PR Newswire
Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture
From PR Newswire
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening
From PR Newswire
Denali Therapeutics Reports First Quarter 2021 Financial Results and Business Highlights
From GlobeNewswire News Releases
First Week of DNLI March 2022 Options Trading
Tags Stocks
From Market News Video
Denali Therapeutics Presents Positive Results from Phase 1 and Phase 1b Studies of Its LRRK2 Inhibitor, BIIB122/DNL151, Supporting Late-Stage Development Plans in Parkinson’s Disease
From GlobeNewswire News Releases
Notable ETF Inflow Detected - IWM, NTLA, LSCC, DNLI
Tags ETFs
From ETF Channel
Implied FNX Analyst Target Price: $109
Tags ETFs
From ETF Channel
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.